Bioventus Inc.
BVS
$7.45
-$0.15-1.97%
NASDAQ
| 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/31/2024 | 09/28/2024 | |
|---|---|---|---|---|---|
| Net Income | 161.08% | 129.04% | 46.07% | 97.44% | 29.28% |
| Total Depreciation and Amortization | -7.10% | -7.95% | 0.68% | 0.35% | -11.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -16.67% | -- |
| Total Other Non-Cash Items | 32.72% | -73.20% | 42.27% | 31.47% | 166.67% |
| Change in Net Operating Assets | 2,431.22% | -91.39% | -111.43% | -206.73% | 97.18% |
| Cash from Operations | 191.76% | 71.07% | -221.92% | 86.25% | 224.06% |
| Capital Expenditure | -639.06% | -787.01% | -183.85% | -55.56% | 96.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | 11,216.22% | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -639.06% | -1,677.92% | 17.40% | 4,178.51% | 96.86% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 39.50% | -63.61% | -- | 100.00% |
| Issuance of Common Stock | -82.64% | 116.26% | -15.25% | 598.10% | 39.29% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -34,805.24% | -5,678.95% | -575.20% | 2,603.49% | -13.69% |
| Cash from Financing | -5,618.51% | -86.91% | 122.32% | -306,007.14% | -95.60% |
| Foreign Exchange rate Adjustments | -184.55% | 148.21% | 179.04% | -660.60% | 205.91% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.48% | 48.19% | -59.27% | -114.72% | 532.47% |